This document discusses pharmacodynamics, which is the study of how drugs act on the body and their effects. It describes how drugs can have therapeutic or adverse effects by stimulating, depressing, or replacing certain processes. The main targets of drugs are receptors, ion channels, enzymes, and transporter proteins. Receptors are sites that recognize signals and initiate responses. The document outlines different types of receptors like G-protein coupled, ion channel, enzyme, and nuclear receptors. It also discusses concepts like agonists, antagonists, efficacy, potency, dose-response curves, therapeutic index, and synergistic or antagonistic drug interactions.
Pharmacodynamics is the study of the biochemical and physiological effects of drugs and their mechanisms of action. Pharmacodynamics is often referred to as “what the drug does to the body”.
In order to exert their effects, drugs usually interact in a structurally specific way with a protein receptor or act on physiological processes within the body. This activates a secondary messenger system that produces a physiological effect. Drugs do not create new action but they can only modify (alter) the functions of cells or tissues in body. The drug–receptor complex initiates alterations in biochemical and/or molecular activity of a cell by a process called signal transduction.
Pharmacodynamics is the study of the biochemical and physiological effects of drugs and their mechanisms of action. Pharmacodynamics is often referred to as “what the drug does to the body”.
In order to exert their effects, drugs usually interact in a structurally specific way with a protein receptor or act on physiological processes within the body. This activates a secondary messenger system that produces a physiological effect. Drugs do not create new action but they can only modify (alter) the functions of cells or tissues in body. The drug–receptor complex initiates alterations in biochemical and/or molecular activity of a cell by a process called signal transduction.
Receptor
A protein molecule
Present either in plasma membrane or cytoplasm
Molecule bind to receptor termed as ligand
It may be peptide, neurotransmitter, hormone, drug or toxins
Ligand may be agonist or antagonists
General description about various types of receptor, their classification, mechanism of action and its clinical significance, along with recent advances.
A power point presentation on Pharmacodynamics (what drug does to the body) suitable for undergraduate medical students beginning to study Pharmacology
Definition
Classification and description of each class.
Description of individual receptor.
Forces affecting the drug receptor binding.
Binding of drug receptor affect drug action.
Agonist and antagonist.
Disease due to malfunctioning of receptors.
New drug design based on structure of receptors
Receptor as target for drug discovery.
Drug action not mediated by receptor.
biochemistry and pharmacology, receptors are chemical structures, composed of protein, that receive and transduce signals that may be integrated into biological systems
This PPT covers basic principles of Pharmacodynamics. It includes definition of Rceptors, Agonist, antagonist, partial agonist and Inverse agonist. This PPT includes different types of receptors. Also concept of synergism and antagonism explained.
The extent and rate at which its active moiety is delivered from pharmaceutical form and becomes available in the systemic circulation
Two related drugs are bioequivalent if they show comparable bioavailability and similar times to achieve peak blood concentrations.
The therapeutic index of a drug is the ratio of the dose that produces toxicity to the dose that produces a clinically desired or effective response in a population of individuals:
Receptor
A protein molecule
Present either in plasma membrane or cytoplasm
Molecule bind to receptor termed as ligand
It may be peptide, neurotransmitter, hormone, drug or toxins
Ligand may be agonist or antagonists
General description about various types of receptor, their classification, mechanism of action and its clinical significance, along with recent advances.
A power point presentation on Pharmacodynamics (what drug does to the body) suitable for undergraduate medical students beginning to study Pharmacology
Definition
Classification and description of each class.
Description of individual receptor.
Forces affecting the drug receptor binding.
Binding of drug receptor affect drug action.
Agonist and antagonist.
Disease due to malfunctioning of receptors.
New drug design based on structure of receptors
Receptor as target for drug discovery.
Drug action not mediated by receptor.
biochemistry and pharmacology, receptors are chemical structures, composed of protein, that receive and transduce signals that may be integrated into biological systems
This PPT covers basic principles of Pharmacodynamics. It includes definition of Rceptors, Agonist, antagonist, partial agonist and Inverse agonist. This PPT includes different types of receptors. Also concept of synergism and antagonism explained.
The extent and rate at which its active moiety is delivered from pharmaceutical form and becomes available in the systemic circulation
Two related drugs are bioequivalent if they show comparable bioavailability and similar times to achieve peak blood concentrations.
The therapeutic index of a drug is the ratio of the dose that produces toxicity to the dose that produces a clinically desired or effective response in a population of individuals:
LD 50 is a certain dose is expressed in milligrams of test material weight per kilogram of body weight (BW) test animals that produce 50% mortality in the population response of test animals within a certain time frame.
LC 50 is the median lethal concentration or concentration of a substance in a water that can cause death is estimated at 50% of the population of a particular test organism. LC 50 also illustrates the relationship between several concentrations of test solution with the response (mortality) amounted to 50% of the population in the test biota in the specified time period.
CT or chronic toxicity is the toxicity test that includes observation of stimuli that can obstruct or interfere with the test organism's life is continuously in a relatively long period of time. Chronic toxicity tests should consider things related to life events such as the test organism growth, reproduction etc
Quality Assurance is of Tremendous Importance in Pharma and Health care sector.
A brief of that is try to explain here..
A Trust of the Customer on Product is solely based on the Effective QA
Principles and mechanisms of drug action. Receptor theories and classification of receptors, regulation of receptors. drug
receptors interactions signal transduction mechanisms, G protein–coupled receptors, ion channel receptor, transmembrane enzyme linked receptors,
transmembrane receptor and receptors that regulate
transcription factors, dose response relationship, therapeutic index, combined effects of drugs and factors modifying drug action.
Mechanism of drug action,drug receptor phrmacologyReena Gollapalli
includes various types of receptors, mechanism of action, factors modifying drug action,principles of drug action,all types of drug receptor complex interactions very useful to students and post graduates..
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
Removing Uninteresting Bytes in Software FuzzingAftab Hussain
Imagine a world where software fuzzing, the process of mutating bytes in test seeds to uncover hidden and erroneous program behaviors, becomes faster and more effective. A lot depends on the initial seeds, which can significantly dictate the trajectory of a fuzzing campaign, particularly in terms of how long it takes to uncover interesting behaviour in your code. We introduce DIAR, a technique designed to speedup fuzzing campaigns by pinpointing and eliminating those uninteresting bytes in the seeds. Picture this: instead of wasting valuable resources on meaningless mutations in large, bloated seeds, DIAR removes the unnecessary bytes, streamlining the entire process.
In this work, we equipped AFL, a popular fuzzer, with DIAR and examined two critical Linux libraries -- Libxml's xmllint, a tool for parsing xml documents, and Binutil's readelf, an essential debugging and security analysis command-line tool used to display detailed information about ELF (Executable and Linkable Format). Our preliminary results show that AFL+DIAR does not only discover new paths more quickly but also achieves higher coverage overall. This work thus showcases how starting with lean and optimized seeds can lead to faster, more comprehensive fuzzing campaigns -- and DIAR helps you find such seeds.
- These are slides of the talk given at IEEE International Conference on Software Testing Verification and Validation Workshop, ICSTW 2022.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024Neo4j
Neha Bajwa, Vice President of Product Marketing, Neo4j
Join us as we explore breakthrough innovations enabled by interconnected data and AI. Discover firsthand how organizations use relationships in data to uncover contextual insights and solve our most pressing challenges – from optimizing supply chains, detecting fraud, and improving customer experiences to accelerating drug discoveries.
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
Elevating Tactical DDD Patterns Through Object CalisthenicsDorra BARTAGUIZ
After immersing yourself in the blue book and its red counterpart, attending DDD-focused conferences, and applying tactical patterns, you're left with a crucial question: How do I ensure my design is effective? Tactical patterns within Domain-Driven Design (DDD) serve as guiding principles for creating clear and manageable domain models. However, achieving success with these patterns requires additional guidance. Interestingly, we've observed that a set of constraints initially designed for training purposes remarkably aligns with effective pattern implementation, offering a more ‘mechanical’ approach. Let's explore together how Object Calisthenics can elevate the design of your tactical DDD patterns, offering concrete help for those venturing into DDD for the first time!
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfPaige Cruz
Monitoring and observability aren’t traditionally found in software curriculums and many of us cobble this knowledge together from whatever vendor or ecosystem we were first introduced to and whatever is a part of your current company’s observability stack.
While the dev and ops silo continues to crumble….many organizations still relegate monitoring & observability as the purview of ops, infra and SRE teams. This is a mistake - achieving a highly observable system requires collaboration up and down the stack.
I, a former op, would like to extend an invitation to all application developers to join the observability party will share these foundational concepts to build on:
PHP Frameworks: I want to break free (IPC Berlin 2024)Ralf Eggert
In this presentation, we examine the challenges and limitations of relying too heavily on PHP frameworks in web development. We discuss the history of PHP and its frameworks to understand how this dependence has evolved. The focus will be on providing concrete tips and strategies to reduce reliance on these frameworks, based on real-world examples and practical considerations. The goal is to equip developers with the skills and knowledge to create more flexible and future-proof web applications. We'll explore the importance of maintaining autonomy in a rapidly changing tech landscape and how to make informed decisions in PHP development.
This talk is aimed at encouraging a more independent approach to using PHP frameworks, moving towards a more flexible and future-proof approach to PHP development.
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...Neo4j
Leonard Jayamohan, Partner & Generative AI Lead, Deloitte
This keynote will reveal how Deloitte leverages Neo4j’s graph power for groundbreaking digital twin solutions, achieving a staggering 100x performance boost. Discover the essential role knowledge graphs play in successful generative AI implementations. Plus, get an exclusive look at an innovative Neo4j + Generative AI solution Deloitte is developing in-house.
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdfPeter Spielvogel
Building better applications for business users with SAP Fiori.
• What is SAP Fiori and why it matters to you
• How a better user experience drives measurable business benefits
• How to get started with SAP Fiori today
• How SAP Fiori elements accelerates application development
• How SAP Build Code includes SAP Fiori tools and other generative artificial intelligence capabilities
• How SAP Fiori paves the way for using AI in SAP apps
Threats to mobile devices are more prevalent and increasing in scope and complexity. Users of mobile devices desire to take full advantage of the features
available on those devices, but many of the features provide convenience and capability but sacrifice security. This best practices guide outlines steps the users can take to better protect personal devices and information.
2.
It is the study of physiological & biochemical
effects of drugs & their mechanism of action at
organ system /subcellular /macromolecular levels.
It deals with what the drug does to the body.
Whereas Pharmacokinetics deals with what the body
does to the drug
3.
This may be desirable therapeutic effects or
undesirable adverse effects (A/E)
The A/E may be expected effects of the drug as side
effects or toxicity( Quantitative effect)
Unexpected A/ E are seen as hypersensitivity
( allergy ) or Idiosyncrasy ( Qualitative effect)
4.
Stimulation - Adrenaline on heart/ Pilocarpine on
salivary gland
Depression - Diazepam on CNS/ PPI on Gastric acid
Replacement - Hormones - Insulin , Thyroxin/ levodopa
in parkinsonism
Cytotoxicity - Anticancer drugs , Antibiotics
Irritation
5.
1.
2.
3.
4.
Most drugs act by binding to a particular target
protein as follows:
Receptors
Ion Channels
Enzymes
Carrier or Transport proteins
Certain drugs have no particular target
Eg: Alcohol, GA
6.
7. Receptor
It is a macromolecular or binding site located on the
surface or inside the effector cell that serves to
recognize the signal molecule / drug & initiate the
response to it, but itself has no other function
Sites of receptors- cell membrane, cytoplasm, nucleus
8.
Paul Ehrlich
The idea that drugs act upon specific
sites (receptive substance) began with
John New Port Langley (1852-1926)
of Cambridge.
The word ‘receptor’ was given by
Paul Ehrlich (1854- 1915).
The receptor concept which forms a
key note in the development of
molecular pharmacology became
firmly established by the quantitative
work of
Alfred Joseph Clark
(1885-1941),
a
professor
of
pharmacology at Kings College
London.
10.
Ligand :
Any molecule that binds selectively to a specific
receptor is called ligand
Affinity :
It is the ability of the molecule to bind to a receptor
Intrinsic activity/Efficacy :
It is the ability of the molecule to elicit a response
after binding with the receptor
11. Agonist
Has both affinity and intrinsic activity
IA= +1
Eg : Adrenaline - α & β receptors,
Morphine- opioid receptors
Antagonist
Has affinty but no intrinsic activity (IA=0).
They oppose the action of agonist
Eg : Propronolol- β blocker,
Atropine-M receptor
12. PARTIAL AGONIST:
Have affinity & submaximal intrinsic activity
IA =between 0 & +1
Eg : Nalorphine, Pentazocin on opioid receptors
Inverse Agonists:
These drugs have affinity but produces actions
opposite to those produced by agonist.
IA = between 0 & -1
Eg: Beta Carboline on BZD receptor
14. SPARE RECEPTORS:
These are reserve receptors present in the body,
gets stimulated only at special situations.
SILENT RECEPTORS:
These are receptors to which an agonist binds
but does not produce a response.
15.
Continued use & stimulation of receptors by agonist
drugs may decrease the number and sensitivity of
the receptors.
This phenomenon is called down regulation
Eg: Constant use of β2 agonist (salbutamol) reduce
therapeutic response in Asthma
16.
Continued use and inhibition of receptors by
antagonist drugs, may increase the number and
sensitivity of the receptors.
This phenomenon is called up regulation.
Eg: sudden withdrawal of anti-anginal drug
(Propranolol) may precipitate angina.
17. 1) Ion channel receptor
2) Transmembrane receptor
3) G-protein coupled receptor
4) Nuclear receptor
Receptor which regulate gene transcription.
18. 1. Ion channel linked
2.
Transmembrane linked
3.
G protein linked
4.
Nuclear (gene) linked
19. -Voltage gated ion channel
-Ligand gated ion channel
-Stretch activated ion channel
-Temperature activated ion channel
20.
Protein pores in the
membrane
Ions include Na+, K+, Ca2+ , Cl.
plasma
Nerves, Skeletal & smooth
muscle cells, cardiac tissue
Channels open when there is
Depolarization of membrane
from its resting potential
Voltage gated Na+ Channeleg. Local An.-lidocaine
Voltage Dependent Ca Channel
eg. Nifedipine
21. Protein pores in the
plasma membrane
Ions include Na+, K+, Ca2+ , Cl.
GABA gated Cl- Ion channel - eg. BZD
Glutamate gated cation Ch. (NMDA r)-
eg. Ketamine, Galantamine
Action occurs very fast in millisecond
24. GPCR Structure:
• Single polypeptide chain
threaded back and forth
resulting in serpentine
shaped 7 transmembrane
alpha helices with 3 loops
extracellularly & 3 loops
intracellularly.
1
2
3
4
•There’s a G protein
attached
to
the
cytoplasmic side of the
membrane.
6
5
Gα
GDP
7
β
γ
• Amino
terminal
lies
extracellularly & carboxy
terminal on cytosolic side.
25. Guanine nucleotide binding proteins:
participate in reversible, GTP-mediated interactions.
Common features:
bind GDP and GTP with high affinity, but adopt different
structure depending on the bound nucleotide.
GTP-bound complex has high affinity for other proteins
(“acceptor’), affecting their enzymatic activity
possess intrinsic GTPase activity which converts GTP to
GDP
Contains ,
and subunits
-subunit contains the GTP/GDP binding site,
26.
27.
Gs – Adenyl cyclase Stimulator & Ca channel
opener
Gi – Adenyl cyclase Inhibitor & K+ channel
opener
Gq – Phospholipase C activator
Go – Ca channel inhibitor
32.
Structure:
• Receptors exist as individual
polypeptides
• Each has an extracellular
signal-binding site
• An intracellular tail with a
number of tyrosines & a
single å helix spanning the
membrane
• Receptor action is slow &
occurs in hours
Eg: Insulin receptors, EGF &
NGF, PDGF, ANF, TGF
receptors.
36.
Receptors are seen intracellularly in the cytoplasm,
Agonist(drug) cross cell membrane and bind with receptor
and form Drug Receptor complex .
DR complex moves to nucleus, interact with DNA, regulate
gene transcription , synthesise specific proteins which
produce cellular effects.
Nuclear receptor action is very slow and occurs with in hours
or days
Egs: Corticosteroids, Sex hormones ,Thyroxine,
Vitamin D, Vitamin A
41. 1) Physical
Bulk laxative
eg.- Agar
Osmotic purgative
- Mgso4, Mannitol
Adsorption
- Charcoal
Demulscent
- Glycerine
Astringent
-tannic acids
2) Chemical
-Neutralisation of Gastric Hcl by antacids,
-Chelating agents with Heavy metals
3) Physico-Chemical
-Alcohol
42.
This is a graph showing dose response relation.
Dose is plotted on X-Axis and Response is
plotted on Y-Axis.
There are two types of DRC:
-Graded/simple DRC
- Log DRC
In Log DRC – dose is converted to logarithmic
scale and is plotted
Log DRC is more convenient and used
44.
Large variations in doses can not be plotted on a
single graph paper.
Comparison between other drug responses is not
possible
45.
Being logarithmic scale , less space
only is
required for plotting & large variations of dose
can be recorded on single graph paper.
Comparison between different drug responses
are possible
46.
To compare the efficacy & potency of drugs
To distinguish between Competitive &
Noncompetitive antagonism of drugs
For calculating the Therapeutic Index or Safety
margin of drugs
47.
Efficacy is the maximum effect produced by the
drug. The maximum height of DRC shows the
efficacy. Clinically efficacy is more important.
Potency is the amount of drug required to
produce the response. in case of less potent drug ,
DRC shifts to right.
Steeper slope of DRC indicates marked increase
in response with slight increase in dose
51. % Max response
AG alone
AG + NC ANT
AG + higher dose
NC ANT
Log Drug Concentration
52.
The gap between therapeutic effect DRC and adverse
effect DRC defines the safety margin or therapeutic
index (TI)
It can be calculated as ratio between LD50 and ED50
TI = median Lethal Dose
= LD50
median Effective Dose
ED50
TI should be more than one , it indicates safety of drug.
Greater the TI , more will be the safety of the drug
53.
Median effecive dose means the 50% of test
population showing therpeutic effect.
Median lethal dose means the 50% of test
population showing lethal effect.
Drugs with wide TI – Diazepam , Penicillin
Drugs with narrow TI – Digoxin , Lithium,
phenytoin,Theophyllin
54.
55.
56.
57. This is the dose range of drug bounded by the
dose which produces minimal therapeutic effect
and the dose which produce maximal
acceptable adverse effect.
Also known as Therapeutic Window.
59. Combined effect of Drug
Synergism
Antagonism
-Physical Antagonism
Additive
synergism
Supradditive
synergism
-Chemical Antagonism
-Physiological Antagonism
-Receptor Antagonism
60. 1.
Additive synergism:
If the total effect of drugs is equal to sum of their
individual effects, it is called additive synergism
( eg: 2+2 = 4)
Egs: Aspirin + paracetamol (analgesic effect)
Theophyllin + ephedrine (Br.Asthma)
2.
Supra additive synergism :
If the added up effect is greater than sum of their
individual effects, it is called supra-additive
synergism ( eg: 2+2 > 4)
Egs: Levodopa + carbidopa (Parkinsonism)
61. 1.Physical antagonism:
The effect of one drug is inhibited by physical
property of another drug.
Eg: Charcoal adsorbs poisons on its surface &
useful in alkaloid poisoning
2.Chemical antagonism :
Here two drugs interact chemically and one drug
neutralise the effect of the other.
Egs :Antacids neutralise gastric acidity
Ca EDTA useful in lead poisoning
62. Here two drugs act on different receptors/ sites; but their
pharmacological effects are opposing each other
functionally
Examples:
Histamine (H1) produce bronchospasm
Adrenaline (β2) produce bronchodilation
Insulin reduce blood sugar
Glucagon increase blood sugar
63. A. Competitive reversible
Both agonists & antagonist drugs compete for same
receptor.
Antagonistic effect is completely reversible.
Eg: Morphine & naloxone on opioid receptor
Adrenalin & Prazosin on alpha receptor
65. B. Competitive irreversible
both drugs act on the same receptor . But
Antagonistic effect is not reversible .
Eg: Adrenaline & Phenoxybenzamin (α rec.)
C. Non Competitive antagonism
The drugs act at different sites of the same receptor
or pathway.
Eg: Adrenaline & Verpamil.
66. % Max response
AG alone
AG + NC ANT
AG + higher dose
NC ANT
Log Drug Concentration